ArticleCureus2025
Evaluating the Use of Amoxicillin in Community-Acquired Pneumonia Patients With Low Confusion, Urea, Respiratory Rate, Blood Pressure, and Age ≥65 Years (CURB-65) Scores: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) remains a significant cause of morbidity and mortality worldwide, necessitating precise antibiotic strategies guided by severity assessment tools such as the confusion, urea, respiratory rate, blood pressure, and age ≥65 years (CURB-65) score. This retrospective study evaluated initial antibiotic choices for patients with low CURB-65 scores (0 and 1) at Glenfield Hospital, University Hospitals of Leicester NHS Trust, focusing on the role of amoxicillin in early-stage pneumonia management. Data from 400 patients across various hospital settings in 2023 were analyzed. Co-amoxiclav was the most prescribed antibiotic, used in 226 cases (62.78%), while amoxicillin was prescribed in 46 cases (12.78%). Despite the small sample size and lack of comorbidity adjustment, the study found a high discharge rate (40 patients, or 86.95%) and low readmission rate (four patients, or 8.70%) for patients initially treated with amoxicillin, supporting its potential as a first-line therapy for low-risk CAP. However, broader studies with more comprehensive data are needed to confirm these findings and refine clinical guidelines, including biomarker integration for more precise prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.